Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: Next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase

Chemico-Biological Interactions

Volumn 175, Issue 1-3, 2008, Pages 380-386

  Haigh, Julian R ^a   Johnston, Scott R ^a   Peppernay, Adam ^a   Mattern, Patrick J ^a   Garcia, Gregory E ^a   Doctor, Bhupendra P ^a   Gordon, Richard K ^a   Aisen, Paul S ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Huperzine A; Pyridostigmine bromide; Soman; WRAIR whole blood cholinesterase assay

Indexed keywords

ACETYLCHOLINESTERASE; BUFFER; CHOLINESTERASE; HUPERZINE A; NERVE GAS; ORGANOPHOSPHATE; PLACEBO; PYRIDOSTIGMINE; SOMAN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ERYTHROCYTE; EX VIVO STUDY; EXPOSURE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTOXICATION; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; PROPHYLAXIS;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; AGED; BUTYRYLCHOLINESTERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HUMANS; SESQUITERPENES; SOMAN;

EID: 50649086147     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.04.033     Document Type: Article

References (20)

1. Taylor P. Anticholinesterase agents. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. eleventh edition (2006), McGraw-Hill, New York 201-216
2. Nigg H.N., and Knaak J.B. Blood cholinesterases as human biomarkers of organophosphorus pesticide exposure. Rev. Environ. Contam. Toxicol. 163 (2000) 29-111
3. Ashani Y., Peggins J.O., and Doctor B.P. Mechanism of inhibition of cholinesterases by huperzine A. Biochem. Biophys. Res. Commun. 30 184 (1992) 719-726
4. Raves M.L., Harel M., Pang Y.P., Silman I., Kozikowski A.P., and Sussman J.L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 4 (1997) 57-63
5. Zhang R.W., Tang X.C., Han Y.Y., Sang G.W., Zhang Y.D., Ma Y.X., Zhang C.L., and Yang R.M. Drug evaluation of huperzine A in the treatment of senile memory disorders. Chung Kuo Yao Li Hsueh Pao 12 (1991) 250-252
6. Little J.T., Walsh S., and Aisen P.S. An update on huperzine A as a treatment for Alzheimer's disease. Expert. Opin. Investig. Drugs 17 2 (2008) 209-215
7. Jiang H., Luo X., and Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional medicine origin for the treatment of Alzheimer's disease. Curr. Med. Chem. 10 21 (2003) 2231-2252
8. Cheng D.H., and Tang X.C. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol. Biochem. Behav. 60 (1998) 377-386
9. Wang T., and Tang X.C. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur. J. Pharm. 349 2-3 (1998) 137-142
10. Bai D. Development of huperzine A and B for treatment of Alzheimer's disease. Pure Appl. Chem. 79 4 (2007) 469-479
11. Gordon R.K., Nigam S.V., Weitz J.A., Dave J.R., Doctor B.P., and Ved H.S. The NMDA receptor ion channel: a site for binding of huperzine A. J. Appl. Toxicol. 21 Suppl. 1 (2001) S47-S51
12. Xu S.S., Cai Z.Y., and Qu Z.W. Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol. Sin. 20 (1999) 486-490
13. Qian B.C., Wang M., Zhou Z.F., Chen K., Zhou R.R., and Chen G.S. Pharmacokinetics of tablet huperzine A in six volunteers. Chung Kuo Yao Li Hsueh Pao 16 (1995) 396-398
14. Lallement G., Baille V., Baubichon D., Carpentier P., Collombet J.M., Filliat P., Foquin A., Four E., Masqueliez C., Testylier G., Tonduli L., and Dorandeu F. Review of the value of huperzine A as pretreatment of organophosphate poisoning. Neurotoxicology 23 (2002) 1-5
15. Gordon R.K., Haigh J.R., Garcia G.E., Feaster S.R., Riel M.A., Lenz D.E., Aisen P.S., and Doctor B.P. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem. Biol. Interact. 157-158 (2005) 239-246
16. Doctor B.P., Raveh L., Wolfe A.D., Maxwell D.M., and Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev. 15 1 (1991) 123-128
17. Cohen O., Kronman C., Raveh L., Mazor O., Ordentlich A., and Shafferman A. Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol. Pharmacol. 70 3 (2006) 1121-1131
18. Li W., Li J., and Hu Q. Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. Biomed. Chromatogr. 22 4 (2008) 354-360
19. Eckert S., Eyer P., and Worek F. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 233 (2007) 180-186
20. Eckert S., Eyer P., Mückter H., and Worek F. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds. Biochem. Pharmacol. 72 (2006) 344-357